TY - JOUR
T1 - Japanese Orthopaedic Association (JOA) clinical practice guidelines on the management of soft tissue tumors 2020 - Secondary publication
AU - Kawai, Akira
AU - Araki, Nobuhito
AU - Ae, Keisuke
AU - Akiyama, Toru
AU - Ozaki, Toshifumi
AU - Kawano, Hirotaka
AU - Kunisada, Toshiyuki
AU - Sumi, Minako
AU - Takahashi, Shunji
AU - Tanaka, Kazuhiro
AU - Tsukushi, Satoshi
AU - Naka, Norifumi
AU - Nishida, Yoshihiro
AU - Miyachi, Mitsuru
AU - Yamamoto, Norio
AU - Yoshida, Akihiko
AU - Yonemoto, Tsukasa
AU - Yoshida, Masahiro
AU - Iwata, Shintaro
N1 - Funding Information:
To elucidate the epidemiology and real-world clinical practices for bone and soft tissue tumors in Japan, a nationwide bone tumor registry was initiated in the early 1960s, and malignant soft tissue tumor registry was started in 1985 with financial support from the Japanese Orthopaedic Association [ 9 ]. The headquarters of the registrations were located in the Department of Musculoskeletal Oncology, National Cancer Center Hospital. In 2008, benign soft tissue tumor cases started to be registered. The registration data were published as a national bone and soft tissue tumor registry digest each year and provide valuable epidemiological information on bone and soft tissue tumors in the country.
Funding Information:
Toshiyuki Kunisada reports a research grant from Kuraray , and the Department of Medical Materials for Musculoskeletal Reconstruction is an endowment department, supported with an unrestricted grant from Kyocera.
Funding Information:
Shunji Takahashi reports honoraria from Eisai , Novartis , Taiho, Astrazeneca , Chugai , Bayer , Daiichi-Sankyo, and research grants from EISAI, Novartis, Taiho, Astrazeneca, Chugai, Bayer, Daiichi-Sankyo, Ono pharmaceutical , IQVIA and Bristol-Myers-Squib .
Funding Information:
Akira Kawai reports research grants from Daiichi-Sankyo, Eli-Lilly, Taiho, Takara-Bio and Japanese Orthopaedic Association.Hirotaka Kawano reports honoraria from Daiichi Sankyo and Hisamitsu, and research grants from Japanese Orthopaedic Association, Nakatomi Foundation, Daiichi-Sankyo, Kyocera, Shionogi, Teijin, Zimmer Biomet, Johnson and Johnson, Smith and Nephew, Peter Blehm Japan and Stryker Japan.Toshiyuki Kunisada reports a research grant from Kuraray, and the Department of Medical Materials for Musculoskeletal Reconstruction is an endowment department, supported with an unrestricted grant from Kyocera.Shunji Takahashi reports honoraria from Eisai, Novartis, Taiho, Astrazeneca, Chugai, Bayer, Daiichi-Sankyo, and research grants from EISAI, Novartis, Taiho, Astrazeneca, Chugai, Bayer, Daiichi-Sankyo, Ono pharmaceutical, IQVIA and Bristol-Myers-Squib.Kazuhiro Tanaka belongs to an endowment department supported with grants from Teijin Nakashima Medical Co., Ltd. and Meditec Co., Ltd.Norio Yamamoto belongs to an endowed department supported with grants from Zimmer Biomet G.K. and Hisamitsu Pharmaceutical Co., Inc.
Funding Information:
Hirotaka Kawano reports honoraria from Daiichi Sankyo and Hisamitsu , and research grants from Japanese Orthopaedic Association, Nakatomi Foundation , Daiichi-Sankyo, Kyocera , Shionogi , Teijin , Zimmer Biomet , Johnson and Johnson , Smith and Nephew , Peter Blehm Japan and Stryker Japan .
Funding Information:
Akira Kawai reports research grants from Daiichi-Sankyo , Eli-Lilly , Taiho , Takara-Bio and Japanese Orthopaedic Association .
Publisher Copyright:
© 2022 The Authors
PY - 2022
Y1 - 2022
N2 - Background: These clinical practice guidelines are intended to provide recommendations based on the best evidence obtained to date on key issues in clinical practice to improve the prognosis, diagnostic and therapeutic processes for patients with soft tissue tumors. Methods: The Guidelines Development Committee and Systematic Review Committee were composed of a multidisciplinary team of specialists who play an important role in soft tissue tumor care. Clinical questions (CQs) were determined by choosing key decision-making points based on Algorithms for the diagnosis and treatment of soft tissue tumors. The guidelines were developed according to the “Medical Information Network Distribution Service (Minds) Handbook for Clinical Practice Guideline Development 2014” and “Minds Manual for Clinical Practice Guideline Development 2017.” Recommendation strength was rated on two levels and the strength of evidence was rated on four levels. The recommendations were decided based on agreement by 70% or more voters. Results: Twenty-two CQs were chosen by the Guidelines Development Committee. The Systematic Review Committee reviewed the evidence concerning each CQ, a clinical value judgment was added by experts, and the text of each recommendation was determined. Conclusion: We established 22 CQs and recommendations for key decision-making points in the diagnosis and treatment of soft tissue tumors according to the Minds Clinical Practice Guideline development methods. We hope that these guidelines will assist the decision-making of all medical staff engaged in the treatment and diagnosis of soft tissue tumors, and eventually lead to improved soft tissue tumor care in the country.
AB - Background: These clinical practice guidelines are intended to provide recommendations based on the best evidence obtained to date on key issues in clinical practice to improve the prognosis, diagnostic and therapeutic processes for patients with soft tissue tumors. Methods: The Guidelines Development Committee and Systematic Review Committee were composed of a multidisciplinary team of specialists who play an important role in soft tissue tumor care. Clinical questions (CQs) were determined by choosing key decision-making points based on Algorithms for the diagnosis and treatment of soft tissue tumors. The guidelines were developed according to the “Medical Information Network Distribution Service (Minds) Handbook for Clinical Practice Guideline Development 2014” and “Minds Manual for Clinical Practice Guideline Development 2017.” Recommendation strength was rated on two levels and the strength of evidence was rated on four levels. The recommendations were decided based on agreement by 70% or more voters. Results: Twenty-two CQs were chosen by the Guidelines Development Committee. The Systematic Review Committee reviewed the evidence concerning each CQ, a clinical value judgment was added by experts, and the text of each recommendation was determined. Conclusion: We established 22 CQs and recommendations for key decision-making points in the diagnosis and treatment of soft tissue tumors according to the Minds Clinical Practice Guideline development methods. We hope that these guidelines will assist the decision-making of all medical staff engaged in the treatment and diagnosis of soft tissue tumors, and eventually lead to improved soft tissue tumor care in the country.
UR - http://www.scopus.com/inward/record.url?scp=85127306887&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127306887&partnerID=8YFLogxK
U2 - 10.1016/j.jos.2021.11.023
DO - 10.1016/j.jos.2021.11.023
M3 - Article
C2 - 35339316
AN - SCOPUS:85127306887
SN - 0949-2658
JO - Journal of Orthopaedic Science
JF - Journal of Orthopaedic Science
ER -